What Changed Since Our Last Coverage

This isn't the same stay. When Justice Samuel Alito issued a temporary hold on May 4, it had an expiration date — Thursday, May 14. That clock ran out.

The full Supreme Court just replaced it with an indefinite stay. Mifepristone can be prescribed via telehealth and mailed to patients nationwide for as long as Louisiana's lawsuit continues — which could be months or years.

What the Court Actually Said — And Didn't

The majority issued NO written opinion. ZERO explanation. Just an unsigned order blocking the 5th Circuit ruling.

The court also didn't reveal the vote count. We know at least seven justices were on board because only Thomas and Alito publicly dissented. But we don't know if it was 7-2 or 9-0 minus two. That ambiguity is deliberate.

Thomas Went Further Than Anyone Expected

Justice Clarence Thomas didn't just dissent on procedure. He called mifepristone distribution a criminal enterprise.

Specifically, Thomas wrote that drugmakers Danco Laboratories and GenBioPro were not entitled to block a court order "based on lost profits from their criminal enterprise," according to NBC News.

He's invoking the Comstock Act — an 1873 federal anti-obscenity law that bans mailing materials used for abortion. Thomas flagged this argument directly, noting that the law makes it a criminal offense to ship mifepristone for use in abortions, according to CNBC.

If a future administration's Justice Department decides to enforce the Comstock Act, no Supreme Court stay protects mifepristone. A future DOJ doesn't need a court ruling to cut off mail access — it just needs to start prosecuting.

Alito Accused Biden of Sabotaging Dobbs

Alito's dissent was politically sharper. He argued that the Biden administration's 2023 decision to allow mail-order mifepristone was a deliberate attempt to "undermine" the court's 2022 Dobbs ruling that overturned Roe v. Wade, according to NBC News.

He also wrote that Louisiana's abortion ban enforcement has been "thwarted by certain medical providers, private organizations, and states that abhor laws like Louisiana's."

Alito is making the case that abortion-ban states have a legitimate grievance — that federal policy is being weaponized to nullify their laws. That argument will resurface in future litigation.

Louisiana's Actual Complaint Is Concrete

Most coverage frames this as a national abortion access story. The specifics are more targeted.

Louisiana banned abortion, then enacted a 2024 law designating mifepristone and misoprostol as controlled substances with criminal penalties for possession without a prescription, according to CBS News. The state then sued the FDA over its 2021 decision to lift the in-person dispensing requirement.

Louisiana Attorney General Liz Murrill argued that the relaxed FDA rule allowed out-of-state providers to mail pills directly into Louisiana, resulting in more than 1,000 medication abortions in the state — abortions that would have been illegal under state law.

Louisiana's core legal argument: federal regulatory policy is actively circumventing a valid state criminal statute. It's a federalism question rooted in specific enforcement problems.

The FDA Sat This One Out

The FDA took no position before the Supreme Court on whether mail access should be preserved, according to CBS News.

The current administration's FDA — under Trump — declined to defend the Biden-era policy. It neither supported nor opposed the stay. That's a significant development about where federal enforcement priorities may be heading.

The Scale of What's at Stake

Medication abortion accounted for 65% of all clinician-provided abortions in 2023, according to the Guttmacher Institute as cited by CBS News. More than 1.1 million abortions were provided by health care workers last year, including telehealth-to-restricted-states delivery.

Mail access to mifepristone isn't a niche workaround. It's the dominant method. Blocking it wouldn't just inconvenience patients — it would structurally eliminate most abortion access in states where clinics are already gone.

What Mainstream Coverage Is Getting Wrong

Every center-left outlet led with relief. "A win for abortion rights." "Access preserved."

This is a procedural hold, not a ruling on the merits. The court has said nothing about whether Louisiana ultimately wins or loses. The 5th Circuit's underlying order — that the FDA overstepped — is still alive.

The Comstock Act angle deserves more scrutiny. Prosecutorial enforcement of that 1873 law could functionally end mail access without any new court decision.

What Comes Next

Mifepristone stays in the mail for now. The court's majority won't explain itself. The FDA under the current administration won't defend the policy. Two justices are on record calling the distribution criminal.

The legal ground has not stabilized. It's temporarily preserved pending the outcome of Louisiana's underlying lawsuit.